NovelMed announce positive 12-week interim results from phase II trial of Ruxoprubart in adult patients with PNH: Cleveland Wednesday, May 21, 2025, 12:00 Hrs [IST] NovelMed, a cl ...

PNH is not an inherited disease, but it is caused by a change, or mutation, in the PIGA gene. The PIGA gene codes for an enzyme needed to make a chemical that helps anchor proteins to the cell ...

PNH is a rare, acquired hematologic disorder in which Red Blood Cells lack protective surface proteins due to a mutation in the phosphatidylinositol glycan class A (PIGA) gene, leaving them ...

PNH is a rare, acquired hematologic disorder in which Red Blood Cells lack protective surface proteins due to a mutation in the phosphatidylinositol glycan class A (PIGA) gene, leaving them ...

PNH is a rare, acquired hematologic disorder in which Red Blood Cells lack protective surface proteins due to a mutation in the phosphatidylinositol glycan class A (PIGA) gene, leaving them vulnerable ...

These clots are the leading cause of PNH death in untreated people. PNH is not an inherited disease, but it is caused by a change, or mutation, in the PIGA gene. The PIGA gene codes for an enzyme ...

Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is ...

Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...